Alerts & Corrections

AHFS Drug Information/Essentials Update – July 2017

The July update to the AHFS Drug Information/Essentials database has been published. Highlights from this month’s update include:

New Full-Length Monographs

  • Bezlotoxumab (Zinplava®) – 80:04 (Antitoxins and Immune Globulins)
    • Indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.

New First-Release Monographs

  • Sarilumab (Kevzara®) – 92:36 (Disease-modifying Antirheumatic Drugs)
    • Indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.
  • Becaplermin (Regranex®) – 84:16 (Cell Stimulants and Proliferants)
    • Indicated for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply.
  • Prasterone (Intrarosa®) – 68:04 (Adrenals)
    • Indicated for treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

FDA MedWatch Alerts

  • None